Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avelas Biosciences Inc.

www.avelasbio.com

Latest From Curis Inc.

What Could Come After CAR-T? Cue Is Betting On Selective Biologics

Emerging Company Profile: Cue Biopharma, a young biotech formed on the basis of research from the Albert Einstein College of Medicine, is developing biologics engineered to selectively modulate disease-relevant T-cells to treat cancer – technology it has called the "next wave" in cancer immunotherapy.

StartUps and SMEs ImmunoOncology

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?

Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.

Deals Pricing Strategies

J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value

Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.

Financing Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Avelas Biosciences Inc.
  • Senior Management
  • Carmine Stengone, Pres. & CEO
    Jesus Gonzalez, PhD, CSO
    Steven Chen, MD, CMO
  • Contact Info
  • Avelas Biosciences Inc.
    Phone: (858) 750-4700
    11099 N. Torrey Pines Rd.
    Ste. 290
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register